Five decades, one mission: Robert Langer on targeting, AI, and the next era of genetic medicines

“I think genetic medicines will be very useful for rare diseases and genetic defects, but I also see the possibility of treating almost any disease…”

Jokūbas Leikauskas, Editor, Nucleic Acid Insights , speaks with Robert Langer, 2026 Robert A Welch Award in Chemistry Recipient, Institute Professor, Massachusetts Institute of Technology (MIT), about his current work, including the Gates Foundation collaborations on self‑boosting vaccines, shelf‑stable formulations, and microneedle patches for the developing world, as well as extrahepatic nucleic acid delivery, AI‑assisted LNP design, and his outlook on the future of genetic medicines in oncology, rare diseases, and beyond.

Please enter your email to access content Read now